Loading profile
Loading sourced facts.
01 Finding sources
02 Reading evidence
03 Filing the card
Loading profile
01 Finding sources
02 Reading evidence
03 Filing the card
Profluent uses frontier AI models to design new proteins for therapeutics, agriculture, and biomanufacturing.
Raised $150M across disclosed rounds.[2][3][4][9]
Series B closed November 2025, led by Bezos Expeditions.[1][2][3][4][5][9]
post-money valuation is not publicly disclosed.
Named investors include Insight Partners, Air Street Capital, AIX Ventures, Phoenix Venture Partners, Spark Capital, Bezos Expeditions, Altimeter Capital.[7][8][1][2][3][4][5][9]
Ali Madani, Founder and CEO[10][11][16]
Alexander Meeske, Co-Founder[10][11][16]
Hilary Eaton, Chief Business Officer[12][13][14][15][16]
Peter Cameron, SVP, Gene Editing and Translation[12][13][14][15][16]
Aaron Schwartz, General Manager, Emerging Technology[12][13][14][15][16]
Stephen Nayfach
Jul 2026 · endpoints.news
reported
Jul 2026 · press.airstreet.com
reported
Jul 2026 · siliconangle.com
reported
Profluent uses frontier AI models to design new proteins for therapeutics, agriculture, and biomanufacturing.
Isomorphic Labs · isomorphiclabs.com · Competes for AI biotech talent, pharma partnerships, and the thesis that AI models can design therapeutics; Isomorphic raised $600M in 2025.[1]
InSilico Medicine · insilico.com · Overlaps on AI-driven therapeutic design and pharma partnerships; raised $123M in 2025.[1]
Ginkgo Bioworks · ginkgobioworks.com · Overlaps on protein engineering services and agriculture partnerships; Profluent hired Ginkgo's former VP of BD.[14]
Filled in the side panel for invited readers. This card carries sourced facts only.
Jul 2026 · upstartsmedia.com
reported
Jul 2026 · businesswire.com
company
Jul 2026 · fiercebiotech.com
reported